Episode 12 -Alexandra Barratt’ It’s not science or instinct…it’s evidence and personal preferences. That’s really, to me, the heart of shared decision making. ’This week ’s guest has led something of a double life, using both medicine and the media to explore and promote the critical role of evidence in healthcare. Now based at the University of Sydney, Alexandra Barratt’s journey from clinician to journalist to global advocate for evidence based medicine and shared decision-making is a fascinating one.Here she talks with acclaimed journalist and health researcher ,Dr Ray Moynihan, about her varied career and the reasons she’s ended up challenging conventional wisdom. She also talks about her research into the pros and cons of breast cancer screening and questions the widely-accepted idea that early detection is always the best medicine.Listen to this episode onSoundCloud,iTunes,Stitcher or wherever you listen to your favourite podcasts. Find more details and our show notes thepodcast page or follow ontwitter orfacebook.The Recommended Dose is produced by Cochrane Australia and co-published withThe BMJ.Thursday, August 9, 2018
This article describes the scope and quality of evidence related to exercise interventions to improve sleep in women with breast cancer. Fifteen studies met the criteria and 12 were judged to be excellent quality. The most frequent intervention was walking, primarily during the time of chemotherapy. Eleven studies reported postintervention improvement in sleep deficiency. Most yoga, qigong, and dance intervention studies reported no differences between groups. Emerging evidence exists for the effectiveness of aerobic exercise to improve various sleep outcomes in women with breast cancer.
Publication date: September 2018Source: Peptides, Volume 107Author(s): Vahid Khori, Ali Mohammad Alizadeh, Solmaz Khalighfard, Yassaman Heidarian, Hamid KhodayariAbstractOxytocin (OT) has the suppressive effects on breast tumor formation and development. We hypothesized that OT through the NF-κB inhibition can induce the miR-195 up-regulation which it can promote the cell apoptosis and inhibit the cell proliferation. Thirty-two BALB/c female mice were equally divided into four groups to study the effects of OT and atosiban (ATO) (an oxytocin receptor antagonist) on the mammary tumor growth. The animal weight, OT plas…
Objective: To analyze the clinical, pathological, and sociodemographic aspects between triple-negative breast cancer (TNBC) and non-TNBC in a Brazilian cohort and identify potential prognostic factors.
Methods: This hospital-based retrospective cohort study included 447 women with breast cancer treated at referral centers in Southeastern Brazil. Overall and disease-free survival were compared; prognostic factors were evaluated.
Results: Triple-negative breast cancer corresponded to 19.5% of breast cancer diagnosis and was more prevalent among nonwhite and less educated women. The patients …
Conclusions: History of alendronate use is associated with a lower likelihood of bone metastases in postmenopausal women with early breast cancer. Oral bisphosphonate treatment could be sufficient for reducing the risk of bone metastases.
AbstractPurpose of ReviewResearch over the past 25 years has revealed much about the architecture of predisposition to breast and ovarian cancer. There is now a general understanding that there are three broad categories of germline variation that may increase risk. First, there are the “high-penetrance” genes associated with a relative risk f or cancer of greater than 5 and demonstrating an autosomal dominant pattern of inheritance. At the other end of the spectrum are “low-penetrance” common variants. These variants are associated with minor increases in risk (commonly less than a relative r…
ConclusionWe demonstrated that TLG of primary tumors can be useful in predicting pathologic ALN metastasis in IDC patients with cN-ALN.
ConclusionsThese results support assessments of precision medicine-guided targeting of autophagy in treatment of brain metastases in breast cancer patients.
Publication date: 15 November 2018Source: Biosensors and Bioelectronics, Volume 119Author(s): Dimithree Kahanda, Naveen Singh, David A. Boothman, Jason D. SlinkerAbstractThere is a great need to track the selectivity of anticancer drug activity and to understand the mechanisms of associated biological activity. Here we focus our studies on the specific NQO1 bioactivatable drug, ß-lapachone, which is in several Phase I clinical trials to treat human non-small cell lung, pancreatic and breast cancers. Multi-electrode chips with electrochemically-active DNA monolayers are used to track anticancer drug activity in cellul…
Less than half of women receiving trastuzumab underwent guideline-recommended cardiac monitoring, but observers suggest that more tailored monitoring may be the way forward.Medscape Medical News
ConclusionsOur findings support the value of telephone communication to patients in relation to timely follow-up. Future research is needed to evaluate the role of communication in completing the breast cancer screening episode.